PT3914247T - Utilização de migalostato na redução do risco de evento cerebrovascular em pacientes com doença de fabry - Google Patents
Utilização de migalostato na redução do risco de evento cerebrovascular em pacientes com doença de fabryInfo
- Publication number
- PT3914247T PT3914247T PT207082835T PT20708283T PT3914247T PT 3914247 T PT3914247 T PT 3914247T PT 207082835 T PT207082835 T PT 207082835T PT 20708283 T PT20708283 T PT 20708283T PT 3914247 T PT3914247 T PT 3914247T
- Authority
- PT
- Portugal
- Prior art keywords
- migalostat
- patients
- risk
- reducing
- fabry disease
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title 1
- 230000007213 cerebrovascular event Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795524P | 2019-01-22 | 2019-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3914247T true PT3914247T (pt) | 2025-01-23 |
Family
ID=69726736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207082835T PT3914247T (pt) | 2019-01-22 | 2020-01-22 | Utilização de migalostato na redução do risco de evento cerebrovascular em pacientes com doença de fabry |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220087993A1 (https=) |
| EP (2) | EP4523750A3 (https=) |
| JP (2) | JP7680356B2 (https=) |
| AR (1) | AR117861A1 (https=) |
| DK (1) | DK3914247T3 (https=) |
| ES (1) | ES3007212T3 (https=) |
| FI (1) | FI3914247T3 (https=) |
| HR (1) | HRP20250078T1 (https=) |
| HU (1) | HUE069934T2 (https=) |
| LT (1) | LT3914247T (https=) |
| PL (1) | PL3914247T3 (https=) |
| PT (1) | PT3914247T (https=) |
| RS (1) | RS66410B1 (https=) |
| SI (1) | SI3914247T1 (https=) |
| SM (1) | SMT202500034T1 (https=) |
| TW (1) | TW202042812A (https=) |
| WO (1) | WO2020154354A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12594268B2 (en) * | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
-
2020
- 2020-01-20 TW TW109101869A patent/TW202042812A/zh unknown
- 2020-01-22 PL PL20708283.5T patent/PL3914247T3/pl unknown
- 2020-01-22 HU HUE20708283A patent/HUE069934T2/hu unknown
- 2020-01-22 ES ES20708283T patent/ES3007212T3/es active Active
- 2020-01-22 AR ARP200100155A patent/AR117861A1/es unknown
- 2020-01-22 US US17/424,979 patent/US20220087993A1/en active Pending
- 2020-01-22 EP EP24212005.3A patent/EP4523750A3/en active Pending
- 2020-01-22 PT PT207082835T patent/PT3914247T/pt unknown
- 2020-01-22 EP EP20708283.5A patent/EP3914247B1/en active Active
- 2020-01-22 RS RS20250066A patent/RS66410B1/sr unknown
- 2020-01-22 FI FIEP20708283.5T patent/FI3914247T3/fi active
- 2020-01-22 JP JP2021542102A patent/JP7680356B2/ja active Active
- 2020-01-22 DK DK20708283.5T patent/DK3914247T3/da active
- 2020-01-22 SI SI202030569T patent/SI3914247T1/sl unknown
- 2020-01-22 LT LTEPPCT/US2020/014531T patent/LT3914247T/lt unknown
- 2020-01-22 HR HRP20250078TT patent/HRP20250078T1/hr unknown
- 2020-01-22 SM SM20250034T patent/SMT202500034T1/it unknown
- 2020-01-22 WO PCT/US2020/014531 patent/WO2020154354A1/en not_active Ceased
-
2025
- 2025-05-08 JP JP2025077689A patent/JP2025128105A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3914247T3 (pl) | 2025-04-14 |
| EP3914247B1 (en) | 2024-11-13 |
| ES3007212T3 (en) | 2025-03-19 |
| FI3914247T3 (fi) | 2025-02-16 |
| RS66410B1 (sr) | 2025-02-28 |
| LT3914247T (lt) | 2025-01-27 |
| SI3914247T1 (sl) | 2025-03-31 |
| HRP20250078T1 (hr) | 2025-03-28 |
| DK3914247T3 (da) | 2025-01-27 |
| SMT202500034T1 (it) | 2025-03-12 |
| HUE069934T2 (hu) | 2025-04-28 |
| EP3914247A1 (en) | 2021-12-01 |
| WO2020154354A1 (en) | 2020-07-30 |
| JP2022518733A (ja) | 2022-03-16 |
| EP4523750A3 (en) | 2025-06-11 |
| JP2025128105A (ja) | 2025-09-02 |
| US20220087993A1 (en) | 2022-03-24 |
| TW202042812A (zh) | 2020-12-01 |
| AR117861A1 (es) | 2021-09-01 |
| JP7680356B2 (ja) | 2025-05-20 |
| EP4523750A2 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201900797D0 (en) | Use of cannabinoids in the treatment of comorbidities associated with epilepsy | |
| LT4014976T (lt) | Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas | |
| IL264301A (en) | Treatment of Fabry disease in ert-naive and ert-experienced patients | |
| IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| IL246579A0 (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| HUE065152T2 (hu) | Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében | |
| SG11202001707PA (en) | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease | |
| IL289167A (en) | The history of 2h-indazole and their use in the treatment of diseases | |
| SI3749308T1 (sl) | Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom | |
| IL273470A (en) | Semaglutide in medical treatment | |
| SG11202000423XA (en) | Treatment of fabry disease in ert-naïve and ert-experienced patients | |
| LT3914247T (lt) | Migalostato vartojimas mažinant smegenų kraujotakos sutrikimo riziką pacientams, sergantiems fabri liga | |
| SG11202103806VA (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| IL270788A (en) | Sulfonylurea compounds in the treatment of disease associated with uv-induced damage | |
| EP3661494B8 (en) | Use of tasimelteon for the treatment of affective disorders in majority black african patients | |
| PL3352777T3 (pl) | Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona | |
| GB202011126D0 (en) | Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy | |
| GB2572652B (en) | Improvements in bedside assist handrails and their attachment | |
| IL284074A (en) | Decorin for use in the treatment of diabetes | |
| GB201817442D0 (en) | Improvements in bedside assist handrails and their attachment | |
| GB201902087D0 (en) | Medicament and the use thereof | |
| GB201802743D0 (en) | Medicament and use thereof | |
| GB201503897D0 (en) | Modifying the body's physiological and psychological response to alcohol |